Scholar
Marketplace
Lab
Feedback
$
English
Sign In
Home
Search
My boards
Insights
Collaborators
Reader
Blog
Help
Home
Search
My boards
Insights
Collaborators
Reader
Blog
Help
Serum creatinine and albumin predict sarcoma-specific survival in patients with myofibroblastic and fibroblastic sarcomas.
Translate
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bengali
Bosnian
Български
Catalan
Cebuano
中文(简体)
中文(繁體)
Corsican
Czech
Danish
Dutch
English
Esperanto
Estonian
Finnish
Français
Georgian
Deutsch
Greek
Haitian Creole
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Kazakh
Khmer
Korean
Kyrgyz
Lao
Latin
Latvian
Lithuanian
Luxembourgish
Macedonian
Malay
Maltese
Maori
Mongolian
Myanmar (Burmese)
Nepali
Norwegian
Pashto
Persian
Polish
Portuguese
Romanian
Russian
Samoan
Serbian
Sinhala
Slovak
Slovenian
Somali
Spanish
Swahili
Swedish
Tajik
Tamil
Thai
Turkish
Ukrainian
Urdu
Uzbek
Vietnamese
Xhosa
Zulu
Anke Scharrer
Joannis Panotopoulos
Madeleine Willegger
Philipp Theodor Funovics
Reinhard Windhager
+4 authors
Journal:
2017/June
-
Journal of Orthopaedic Research
ISSN:
1554-527X
PUBMED:
28485477
DOI:
10.1002/jor.23598
Abstract:
Recent evidence suggests that common prognostic factors predicting disease progression and survival in soft tissue sarcomas (STS) are not applicable to all STS entities, indicating the need for histotype specific evaluation of new prognosticators. This study aimed at evaluating preoperative serum creatinine, albumin, and the albumin-creatinine ratio (ACR) as markers for survival in patients with malignant fibroblastic and myofibroblastic sarcomas. One hundred and thirty-two patients who underwent sarcoma resection have been included. Statistical analysis comprised uni- and multivariable Cox proportional hazard models, competing risk analysis and Kaplan-Meier estimates. The 5-year overall survival (OS) was estimated at 64.1% (95%CI: 53.7-72.8) and the 5-year sarcoma-specific mortality was 19.9% (95%CI: 12.8-28.1). Elevated serum creatinine levels were significantly associated with an impaired sarcoma-specific survival (SSS) adjusted for tumor stage (subdistribution hazard ratio (SHR) per 1 mg/dl increase: 3.27; 95%CI: 1.87-5.73; p < 0.0001). Low serum albumin levels were associated with a shorter recurrence-free survival (RFS) experience (HR per 10 g/L increase: 0.62; 95%CI: 0.41-0.94; p = 0.024). The ACR emerged as an AJCC-stage-independent prognosticator of SSS (SHR per 1 unit increase: 0.94; 95%CI: 0.90-0.98; p = 0.003). In conclusion, serum albumin and creatinine have been confirmed as predictive biomarkers for disease-specific outcomes in myofibroblastic and fibroblastic sarcomas. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 35:2815-2824, 2017.
Open in
PUBMED
|
DOI
|
Google Scholar
|
Wikipedia
Relations:
Citations
(8)
Drugs
(1)
Affiliates
(2)
Similar articles
Articles by the same authors
Discussion board
Collaboration tool especially designed for Life Science professionals.
Drag-and-drop any entity to your messages.
Learn More
Search and select entities to see details here. Details will include lists of related entities (via publication). Explore related entities further.
Learn More